The Diplomat in Spain
  • Frontpage
  • News
    • Spain
    • World
    • The world in Spain
    • Diplomatic Breakfast
    • Diplomacy with a history
    • The bag
    • Social life
    • Appointments
  • Tribune
  • VIP Club
  • Embassies
    • Embassies Directory
    • Protocol
    • International legislation
  • Discover Spain
  • UNWTO News
  • Leisure
    • Culture & Art
    • Entertainment
    • Movies
  • es Español
  • en English
  • Account
No Result
View All Result
  • Frontpage
  • News
    • Spain
    • World
    • The world in Spain
    • Diplomatic Breakfast
    • Diplomacy with a history
    • The bag
    • Social life
    • Appointments
  • Tribune
  • VIP Club
  • Embassies
    • Embassies Directory
    • Protocol
    • International legislation
  • Discover Spain
  • UNWTO News
  • Leisure
    • Culture & Art
    • Entertainment
    • Movies
No Result
View All Result
The Diplomat in Spain
No Result
View All Result

China’s new drug might give Alzheimer patients hope: lead researcher

October 28, 2018
in Health, VIP Club

 

GV-971, a multi-targeting oligosaccharide drug developed by a Chinese research group, could give Alzheimer patients hope, lead researcher Geng Meiyu told Xinhua on Thursday.

 

“If everything is confirmed in future studies, this can really give the world new hope,” she said.

 

Geng, key inventor of the GV-971, presented the findings in a speech on Thursday at the 11th Clinical Trials on Alzheimer’s Disease Conference (CTAD) being held in Barcelona until Oct. 27.

 

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory, thinking skills, and the ability to carry out simple tasks. The disease affects about 48 million people worldwide, and the number is expected to increase with the aging population. There is no effective cure.

 

GV-971 was developed by Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Green Valley Pharmaceutical Co., Ltd, after a 21-year study.

 

The drug completed phase 3 clinical trial in July this year. A phase three clinical trial is the last test before reaching the market.

 

In the trial, participants took 450 mg GV-971 orally twice a day for 36 weeks, which proved effective in improving cognition.

 

Extracted from brown algae, the drug is targeted at patients with mild-to-moderate Alzheimer’s. Independent animal experiments also showed that it can regulate the immune system, reduce neuro-inflammation and improve cognition.

 

“In the future we will confirm our findings in human bodies,” Geng said. The launch of a new drug like GV-971 would give hopes to patients not only in China but in other parts of the world, she added.

 

 

ShareTweetSend
Previous Post

How Glasses Make It Easier For Children To Learn

Next Post

Cuba in the crossway

The bag

Óscar Maúrtua, dismissed as Peru’s ambassador to Spain

The Peruvian government of President Dina Boluarte has dismissed the ambassador to Spain, Óscar Maúrtua de Romaña, who also served as ambassador to Andorra and

More bags>

Hemeroteca

Receive our newsletter

We use MailChimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to MailChimp for processing. Learn more about MailChimp's privacy practices here.

  • Contacto
  • ¿Quiénes somos?
  • Aviso legal y Propiedad intelectual

© The Diplomat in Spain. All rights reserved.

  • English
  • Español (Spanish)
Account
  • Frontpage
  • News
    • Spain
    • World
    • The world in Spain
    • Diplomatic Breakfast
    • Diplomacy with a history
    • The bag
    • Social life
    • Appointments
  • Tribune
  • VIP Club
  • Embassies
    • Embassies Directory
    • Protocol
    • International legislation
  • Discover Spain
  • UNWTO News
  • Leisure
    • Culture & Art
    • Entertainment
    • Movies

© The Diplomat in Spain. All rights reserved.

Tanto nuestros partners como nosotros utilizamos cookies en nuestro sitio web para personalizar contenido y publicidad o analizar nuestro tráfico. Haciendo click consientes el uso de esta tecnología en nuestra web. Saber más